



Monday March 9, 2009
18:00 to 19:30

Lyon Convention Center
France

PUBLIC PRIVATE PARTNERSHIP: A DRIVING FORCE FOR THE FUTURE

Moderator

- **Elizabeth J. Padmore**, Board member, Independent Consultant and Associate Fellow James Martin Institute, UK

Speakers

- **Amir A. Dossal**, Executive Director, UN Office for Partnerships
- **Koichi Kitazawa**, President, Japan Science and Technology Agency
- **Alain Mérieux**, President, Mérieux Alliance, France
- **Wayne F. Pisano**, President and CEO, Sanofi Pasteur, France

Summary

Public action is required for projects that are socially valuable but not economically viable

- E.g.: in Western countries, citizens do not pay attention anymore to nearly-eradicated infectious diseases. Therefore, the 'natural' market demand for vaccination fades away and the public health authorities must jump in to sustain immunization efforts.

In addressing health issues, large PPPs have led to noticeable successes:

- One of the most famous is the GAVI initiative leveraging public funds as well as funds from private foundations and coordinating several public and private organizations for delivery of vaccine immunization
- Another example is the A2I/OSEO French agency which elected a €400mio "theranostic" program for public funding, in which the French government is funding 23% with the approval of the EU – an example of research that a public listed company could not do on its own

On the other end, field focused PPPs are also applicable:

- E.g. development of veterinarian vaccines against foot mouth disease required a field approach – due to high strain variations – and a close cooperation with local authorities in charge of animal health, regulatory approval, farmer funding, etc.
- The same applied when a specific country faced a genuine health issues - as was the case for Brazil with a meningitis outbreak: a swift partnership enabled the health authorities to get 6 mio doses of Men AC vaccines produced within six months using local strains

Hurdles to overcome:



Capgemini Consulting is the strategy and transformation consulting brand of Capgemini Group

- IP – need to look at the circumstances and how you provide the access – example, in the case of pre-pandemic vaccines, the private industry has the capacity to manufacture the antigen but not the capacity to fill, package and distribute the vaccine which can be done locally
- Corruption – be very careful with who you work with – work with the local citizens – you find fantastic people that are motivated and fighting for the case
- The distrust that multinational are only in it for money
- The need for fast return can be a barrier – a long term sustainable view is needed – when you save a child he will eventually become a consumer
- The public need to look into how the private can benefit from investing in the poor

Receipts for successful Public Private Partnerships:

- Understand where we are coming from and where we want to go – a common goal
- Focusing on transparency and delivery of results
- Leveraging the expertise from each of the partners
- Each partner has its share of voice - example is where UN created GAVI as a partnership with its own ad-hoc governance

Quotes

"A lot of this is about trust. The "polio vaccine story" shows how misinterpretation can have fatal consequences."
Elizabeth Padmore

"Japan has a long experience and tradition of successful collaboration between the technocracy and private industry."
Koichi Kitazawa

"Financial analysts do not like research and without the partnership we would disappear and get no solutions to the complex issues."
Alain Mérieux

"When all the constituents are harmonized on the goal, we can have powerful results."
Wayne Pisano

"When it came to distribution network, the private sector brought the market rigor."
Amir Dossal